These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26275461)

  • 1. Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1.
    Liu R; Li J; Lai Y; Liao Y; Liu R; Qiu W
    Int J Biol Macromol; 2015 Nov; 81():491-7. PubMed ID: 26275461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development.
    Jin C; Yan B; Lu Q; Lin Y; Ma L
    Tumour Biol; 2016 Jun; 37(6):7383-94. PubMed ID: 26676637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
    Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
    Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MALAT1-miR-124-RBG2 axis is involved in growth and invasion of HR-HPV-positive cervical cancer cells.
    Liu S; Song L; Zeng S; Zhang L
    Tumour Biol; 2016 Jan; 37(1):633-40. PubMed ID: 26242259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1.
    Han Y; Liu Y; Zhang H; Wang T; Diao R; Jiang Z; Gui Y; Cai Z
    FEBS Lett; 2013 Nov; 587(23):3875-82. PubMed ID: 24396870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer.
    Li QW; Zhou T; Wang F; Jiang M; Liu CB; Zhang KR; Zhou Q; Tian Z; Hu KW
    Genet Mol Res; 2015 Dec; 14(4):16133-45. PubMed ID: 26662405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.
    Cai C; Chen QB; Han ZD; Zhang YQ; He HC; Chen JH; Chen YR; Yang SB; Wu YD; Zeng YR; Qin GQ; Liang YX; Dai QS; Jiang FN; Wu SL; Zeng GH; Zhong WD; Wu CL
    Clin Cancer Res; 2015 Nov; 21(21):4922-34. PubMed ID: 26080838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
    Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
    J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A.
    Yin Y; Zhang B; Wang W; Fei B; Quan C; Zhang J; Song M; Bian Z; Wang Q; Ni S; Hu Y; Mao Y; Zhou L; Wang Y; Yu J; Du X; Hua D; Huang Z
    Clin Cancer Res; 2014 Dec; 20(23):6187-99. PubMed ID: 25294901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma.
    Liu P; Yang H; Zhang J; Peng X; Lu Z; Tong W; Chen J
    Sci Rep; 2017 Jul; 7(1):5186. PubMed ID: 28701723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer.
    Wang SH; Zhang WJ; Wu XC; Weng MZ; Zhang MD; Cai Q; Zhou D; Wang JD; Quan ZW
    J Cell Mol Med; 2016 Dec; 20(12):2299-2308. PubMed ID: 27420766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells.
    Cheng Y; Li Y; Nian Y; Liu D; Dai F; Zhang J
    BMC Cancer; 2015 Apr; 15():306. PubMed ID: 25928665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA RP11-79H23.3 Functions as a Competing Endogenous RNA to Regulate PTEN Expression through Sponging hsa-miR-107 in the Development of Bladder Cancer.
    Chi H; Yang R; Zheng X; Zhang L; Jiang R; Chen J
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer.
    Zhang R; Guo Y; Ma Z; Ma G; Xue Q; Li F; Liu L
    Oncotarget; 2017 Apr; 8(16):26079-26089. PubMed ID: 28212532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.
    Li Q; Zhang C; Chen R; Xiong H; Qiu F; Liu S; Zhang M; Wang F; Wang Y; Zhou X; Xiao G; Wang X; Jiang Q
    Cancer Lett; 2016 Dec; 383(1):28-40. PubMed ID: 27693631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-β1 promotes breast cancer metastasis by downregulating miR-196a-3p expression.
    Chen Y; Huang S; Wu B; Fang J; Zhu M; Sun L; Zhang L; Zhang Y; Sun M; Guo L; Wang S
    Oncotarget; 2017 Jul; 8(30):49110-49122. PubMed ID: 28418877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer.
    Qin Y; Dang X; Li W; Ma Q
    Oncol Res; 2013; 21(6):353-63. PubMed ID: 25198665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.